{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lim WW"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","US Centers for Disease Control and Prevention","RGC Senior Research Fellow Scheme","Research Grants Council"],"pagination":["152-160"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11272062"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["230(1)"],"pubmed_abstract":["<h4>Background</h4>The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.<h4>Methods</h4>We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.<h4>Results</h4>The proportions of vaccine efficacy mediat"],"journal":["The Journal of infectious diseases"],"pubmed_title":["Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections."],"pmcid":["PMC11272062"],"funding_grant_id":["75D301-23-C-17596","T11-712/19-N","R01 AI170116","HKU SRFS2021-7S03"],"pubmed_authors":["Lim WW","Wong SS","Cowling BJ","Feng S","Sullivan SG"],"additional_accession":[]},"is_claimable":false,"name":"Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.","description":"<h4>Background</h4>The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.<h4>Methods</h4>We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.<h4>Results</h4>The proportions of vaccine efficacy mediat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-03T01:26:16.556Z","creation":"2025-04-06T22:20:54.544Z"},"accession":"S-EPMC11272062","cross_references":{"pubmed":["39052734"],"doi":["10.1093/infdis/jiae122"]}}